Foresee Pharmaceuticals Co., Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2014
NCT02234115
First Marketed Drug
2021
leuprolide (lupron)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Foresee Pharma | Foresee Pharmaceuticals Co., Ltd. | FORESEE PHARMS